Introduction
Leiomyosarcomas, malignant tumors arising from smooth muscle cells, and rhabdomyosarcomas, arising from striated muscle cells, are aggressive malignancies that respond poorly to chemotherapy.
These tumors may produce IGF-I and especially IGF-II. In leiomyosarcomas IGF-II overexpression may be caused by relaxation of IGF-II genomic imprinting (Vu et al., 1995) and may induce lifethreatening hypoglycemia in the affected patients (Strauss et al., 1994) .
In a variety of malignancies autocrine/paracrine IGF-II secretion may play an important role in tumor progression by stimulating growth and migration and protecting cells from apoptosis . IGF-II is believed to exert biological effects by binding to and activating the type I IGF receptor (IGF-IR) (Cullen and Lippman, 1992; Osborne et al., 1989) . However, we recently demonstrated that IGF-II also binds and activates one of the two isoforms of the insulin receptor (isoform A or IR-A) with a similar affinity than IGF-IR . Both the insulin receptor (IR) and the IGF-IR are tetrameric glycoproteins composed of two extracellular a-and two transmembrane b-subunits with intrinsic tyrosine kinase activity. These receptors share more than 50% overall amino acid sequence homology and 84% homology in the tyrosine kinase domains (Ullrich et al., 1986) . The relative abundance of the two IR isoforms is tightly regulated and the IR-A isoform appears to be predominantly expressed in fetal tissues, where it is partially responsible for IGF-II induced growth . IR-B, in contrast, is predominantly expressed in normal adult tissues, but not in a variety of epithelial human malignancies (including cancers of the colon, lung, breast and thyroid), where IR-A expression predominates and may potentiate the biological effects of autocrine/paracrine production of IGF-II . In thyroid cancer, both the IGF-II autocrine production and the relative abundance of IR-A progressively increase with tumor de-differentiation, underscoring the possible relevance of this autocrine loop in tumor progression (Vella et al., 2002) .
In non-epithelial malignancies this autocrine/paracrine loop involving IGF-II and IR-A has not been investigated. In the present study we evaluated the possible relevance of such a loop in myosarcomas. Since both leiomyosarcoma and rhabdomyosarcoma cells secrete substantial amounts of IGF-II (El-Badry et al., 1990) , we analysed the IR expression in these cells and found that they predominantly express IR-A. Moreover, in a leiomyosarcoma cell line (SKUT-1), which is IGF-IR deficient, we studied IR-A mediated IGF-II biological effects in the absence of the interfering activity of IGF-IR. In these cells insulin and IGF-II had a different potency in activating different signaling pathways and eliciting different biological effects. Insulin was more effective than IGF-II in activating the IRS-1/AKT pathway and protecting cells from apoptosis while IGF-II was more effective in activating the Shc/ERK pathway and stimulating cell invasion.
Results

IGF-I and IGF-II secretion and cognate receptor expression in myosarcoma cells
Myosarcoma cells secrete IGF-II but not IGF-I We first measured IGF-I and IGF-II mRNA in cell lines by RT -PCR in six myosarcoma cell lines, including three leiomyosarcoma cell lines (MESSA, SK-LMS-1 and SKUT-1) and three rhabdomyosarcoma cell lines (A204, . IGF-I mRNA was absent in all myosarcoma cultures, while present in a control cell line. In contrast, IGF-II mRNA was present in all cell lines (data not shown). IGF-II protein secretion was then measured in cell conditioned medium by an immunoradiometric assay and high levels were found in all cultures (Table 1) .
In myosarcoma cells IR and IGR-IR are expressed at variable levels: SKUT-1 cells express IR but are IGF-IR deficient We measured IR and IGF-IR by both Western blot analysis and ELISA, using specific antibodies. The two receptors were not evenly expressed in the six cell lines: four cell lines consistently expressed both IR and IGF-IR; SKUT-1 cells expressed relatively high levels of IR while IGF-IR was undetectable; in contrast, RD cells expressed relatively high levels of IGF-IR but IR only in trace amounts ( Figure 1 , Table 2 ).
IRs are predominantly expressed as the IGF-II sensitive IR-A isoform The relative abundance of the two IR isoforms was then evaluated by RT -PCR. IR-A was the predominant isoform in all myosarcoma cell lines with the exception of the leiomyosarcoma cell line MESSA (Table 2, Figure 2 ). Remarkably, IR-A represented approximately 95% of total IR in leiomyosarcoma SKUT-1 cells and it was the only IR isoform expressed in RD and SJRH-30 rhabdomyosarcoma cells (Table 2, Figure 2 ).
Taken together, these data indicate that human myosarcoma cells produce large amounts of IGF-II, but not IGF-I, and that they express IR predominantly or exclusively as IR-A, the IR isoform with high affinity for IGF-II. These data suggest that IR-A may be an important target of autocrine IGF-II.
Both insulin and IGF-II activate IR-A signaling pathway in IGF-IR-deficient SKUT-1 cells IGF-IR-deficient SKUT-1 cells were then used to evaluate the IGF-II ability to activate the IR-A signaling pathway and to induce biological effects in these cells. MESSA and SJRH-30 cells, that express Figure 3a ). IGF-I was less effective (11% of insulin stimulation). Dose -response studies carried out by ELISA in cell lysates from ligand stimulated SKUT-1 indicated that the ED 50 for IR autophosphorylation was 0.8 nM and 2.5 nM for insulin and IGF-II, respectively (data not shown). In SJRH-30 cells (IR-A&100%, IGF-IR present) insulin and IGF-II were almost equipotent for IR activation ( Figure  3b ), while in MESSA cells (IR-A=40%, IGF-IR present) IGF-II was much less potent than insulin ( Figure 3c ). As expected, in both cell lines IGF-I was much less potent than insulin or IGF-II in activating the IR. When lysates from ligand-stimulated SKUT-1 cells were immunoprecipitated with an anti-IGF-IR antibody and blotted with an anti-Py antibody, no phosphorylation was observed (Figure 4a ). No IGF-IR phosphorylation was also found by ELISA (data not shown), confirming the absence of functional IGF-IR in SKUT-1 cells. In contrast, both IGF-I and IGF-II induced IGF-IR autophosphorylation in SJRH-30 and MESSA cells (Figure 4b,c) .
IGF-II biological effects in SKUT-1 cells
To evaluate the biological effects of IGF-II via the IR-A in IGF-IR-deficient SKUT-1, cells were exposed to IGF-II and cell proliferation, apoptosis protection and chemotactic matrix invasion were studied. MESSA and SJRH-30 cells were used for comparison. 2 IR isoform mRNA expression (RT -PCR) in rabdomyosarcoma and leiomyosarcoma cells. RNA was extracted by the acidic phenol method and RT -PCR of IR isoform expression was carried out for 30 cycles. After electrophoresis silver-stained DNA fragments (600 and 636 bp, for IR-A and B, respectively) were quantitated by scanning densitometry (see Table 2 ). 
Cell proliferation
3 H-thymidine incorporation was carried out 24 h after cell exposure to either insulin, IGF-I or IGF-II (10 nM). Ligand-stimulated 3 Hthymidine incorporation in SKUT-1 cells was very low and did not reach statistical significance (Table 3 ). All three ligands were ineffective in MESSA cells, while they were equipotent in inducing cell proliferation in inducing proliferation SJRH-30 cells (Table 3) . Since IGF-II effects may be regulated by the presence of IGF-binding proteins (IGF-BPs), that may either increase or decrease IGF-II bioavailability, we evaluated the effect of Del-IGF-II, a truncated IGF-II analog that does not bind to IGF-BPs. Del-IGF-II and IGF-II had very similar effects on thymidine incorporation (data not shown), indicating that the low/ absent proliferative response to IGF-II is not caused by binding to IGF-BPs.
Cell viability and apoptosis assays We then evaluated whether IGF-II was able to protect cells from apoptosis induced by the absence of serum in the culture medium. The cumulative effect of apoptosis over time was assessed by MTT assay. This assay measures the rate of tetrazolium salt reduction to formazan, which is proportional to the number of viable cells. In the absence of significant cell proliferation, differences in viable cells are determined by differences in the apoptosis rate. To assess the possible relevance of autocrine IGF-II production, SKUT-1 cells were cultured in monolayers in serum freemedium and MTT staining was evaluated at 6, 9 and 12 days in the presence of 2 mg/ml of IGF-II blocking antibody or control antibody 4G10. Unstimulated cell viability was decreased by IGF-II blocking antibody but not by the control antibody, suggesting that IR activation by autocrine IGF-II production may sustain cell viability (Figure 5a ). Similar results were also obtained by blocking IR activation by HNMPA, a specific inhibitor of the IR tyrosine kinase activity (data not shown).
We then evaluated the possible protective effect of IGF-II on staurosporin-induced apoptosis. Staurosporin, a potent apoptotic agent, was used at 2 nM, a dose able to reduce cell viability by approximately 40% after 4 days (data not shown). SKUT-1 cells unstimulated or stimulated with either insulin or IGF-II (10 nM) were cultured in the presence or the absence of staurosporin and cell viability was assessed by MTT assay 4 days later. In staurosporin exposed cultures cell viability was increased by both insulin and IGF-II, with insulin being slightly more effective (Table 4) .
Protection from staurosporin-induced apoptosis was also evaluated by measuring histone-associated-DNAfragments (mono-and oligonucleosomes), as described in Materials and methods. Results were very similar to those obtained with MTT assay: both ligands effectively reduced apoptosis (P=0.003) and insulin was slightly more effective (Table 4) .
In SJRH-30 cells insulin did not effectively protect from apoptosis, while both IGFs were equally effective (94 vs 68% residual apoptosis, after insulin and IGFs, respectively). MESSA cells were most sensitive to the Cell invasiveness We then compared the ability of both insulin and IGF-II to induce chemoinvasion in SKUT-1 cells. Chemoinvasion was measured as the cell's ability to cross a Matrigel barrier in Boyden chambers. Interestingly, IGF-II was consistently more potent (P50.0001) than insulin in stimulating chemoinvasion, while IGF-I was ineffective (Table 5 ).
Insulin and IGF-II-induced chemoinvasion was effectively blocked by the specific IR tyrosine kinase inhibitor HNMPA (0.5 mM), indicating that the IR tyrosine kinase activity is required for this function and that this biological effect of IGF-II is entirely due to IR activation (Table 5) . Autocrine IGF-II blockade by either an anti-IGF-II antibody or IGF-BP6, significantly (P50.0001) reduced unstimulated cell migration, while incubation with a control antibody was ineffective ( Figure 5b ). All three ligands effectively stimulated chemoinvasion in control cells. In SJRH-30 cells chemoinvasion was stimulated by 157+21%, 173+31% and 198+36% after exposure to insulin, IGF-I and IGF-II, respectively. Corresponding values obtained in MESSA cells were 132+12%, 241+43%, 165+34% (values represent the mean+s.d. of four separate experiments carried out in triplicate). Also in these control cell lines IGF-II was more potent than insulin in stimulating chemonvasiveness.
Insulin predominantly activates the IRS-I/Akt pathway, while IGF-II predominantly activates the Shc/ERK pathway in SKUT-1 cells To explain in SKUT-1 cells the differential biological effects of insulin and IGF-II, with the latter being a more potent stimulator of cell invasiveness, we studied the intracellular pathways activated by either ligand. Intact SKUT-1 cells were exposed to 10 nM of either insulin, IGF-I or IGF-II, for 10 min and the activation of IRS-1/2 docking proteins, of Shc proteins and of the intracellular substrates ERK 1/2 (p42 -p44 MAPkinase) and Akt kinases were subsequently measured by Western blot. IRS-1 was activated by insulin and, to a lower extent, by IGF-II (Figure 6a ). IRS-2 was present at very low levels and phosphorylated IRS-2 was undetectable after either insulin or IGF-II stimulation. In contrast with IRS-1, Shc proteins were activated more effectively by IGF-II than by insulin (Figure 6b ). Moreover, insulin was a more potent stimulator of Akt than IGF-II (P=0.005) while IGF-II was a more potent stimulator of ERK1/2 than insulin (P=0.002) (Figure 7 ). IGF-I was mostly ineffective in SKUT-1 cells except for a slight ERK1/2 stimulation ( Figure 7) .
In IGF-IR containing SJRH-30 cells all three ligands were almost equipotent in stimulating Akt (155+7%, 160+11%, 167+14%, after insulin, IGF-I or IGF-II) with insulin being slightly less effective than IGFs in stimulating ERK1/2 (143+21%, 171+18%, 162+16%, after insulin, IGF-I or IGF-II (data not shown).
To evaluate the involvement of the PI3-kinase/Akt pathway in mediating chemoinvasion, we used LY290042, a reversible inhibitor of PI3-kinase. Cells were preincubated for 30 min with or without LY290042 at increasing concentrations and Akt activation evaluated in response to either insulin or IGF-II. As previously described (see Figure 7) , Akt activation in response to insulin was stronger than after IGF-II. Akt inhibition by LY290042 was dose dependent. A complete inhibition of Akt phosphorylation in response to insulin was observed at 10 -50 mM LY290042 while 2 -10 mM were sufficient to completely block the response to IGF-II (Figure 8a) . A dose of 10 mM LY290042 was, therefore, used in chemoinvasion experiments and was able to almost completely block the cell ability to invade matrigel in response to both insulin and IGF-II (Figure 8b ).
We then studied the effect of the ERK1/2 pathway by using the MEK inhibitor PD98059. First, we evaluated the PD98059 ability to inhibit the ERK1/2 activation in response to the two ligands. As already described (see Figure 7 ) ERK1/2 activation was stronger in response to IGF-II as compared to insulin. PD98059 completely blocked the response to insulin at a dose of 2 mM while 2 -10 mM were required to block the response to IGF-II (Figure 9a ). When chemoinvasion experiment were carried out in the presence of 10 mM PD98059, the response to insulin was inhibited by 80% and the response to IGF-II was inhibited by 86% ( Figure 9b ). We then studied chemoinvasion using a suboptimal dose of inhibitors (2 mM), separately or in combination. LY290042 inhibited the chemoinvasion response to insulin or IGF-II by 90% and 65%, respectively; PD98059 inhibited responses to both stimulators by 70%. A combination of the two inhibitors (2 mM) completely inhibited the insulin response and inhibited by 90% the IGF-II response (data not shown). These data suggest that both the PI3-kinase/Akt and the ERK1/2 pathways have a role in mediating cell invasion in response to insulin or IGF-II. Moreover, they are consistent with the suggestion that the stronger ERK1/2 activation in response to IGF-II is involved in the stronger chemoinvasion response to IGF-II.
Discussion
The main findings of the present study can be summarized as follows: (1) leiomyosarcoma and 4) one of the cell lines studied, SKUT-1, expresses &95% of IR as IR-A, but does not express IGF-IR; (5) in SKUT-1 cells, therefore, both insulin and IGF-II elicit biological effects via IR-A activation, while IGF-I is mostly ineffective; (6) in SKUT-1 cells, insulin is more potent than IGF-II in activating the PI3-K/Akt pathway, while IGF-II is more potent than insulin in activating the Shc/ERK pathway.
These findings in myosarcoma cells follow the observation that IR-A is overexpressed in most human carcinomas Sciacca et al., 1999; Vella et al., 2002) . In the thyroid model, the relative abundance of IR-A progressively increases from normal thyrocytes (that predominantly express IR isoform B) to differentiated papillary thyroid cancer cells and then to undifferentiated thyroid cancer cells that express a very high proportion (over 70%) of IR-A (Vella et al., 2002) . In contrast, the IR-B isoform is predominantly expressed in normal adult tissues, especially in insulintarget tissues of muscle, liver and fat. This study demonstrated that the IR isoform A is also predominantly expressed in fetal tissues, where it behaves as a physiological receptor for IGF-II . The two IR isoforms have been reported to differently couple to PI3-kinase isoforms and to differently activate downstream kinases (Leibiger et al., 2001) . We recently provided evidence that a predominant IR-A expression in cells co-expressing IGF-IR upregulates the IGF system via the formation of IR-A/IGF-IR hybrids that bind to and are activated by insulin, IGF-I and IGF-II with high affinity. In contrast, cells predominantly expressing IR-B, also express IR-B/IGF-IR hybrids that have a reduced affinity for IGFs and binds very little insulin . In HepG2 hepatoblastoma cells proliferation and migration in response to both IGFs were greatly stimulated in cells overexpressing IR-A/IGF-IR but not in cells overexpressing IR-B/IGF-IR .
Our present data show that the newly identified autocrine loop involving IGF-II and IR-A is also active in myosarcomas, poorly differentiated tumors of mesenchymal origin. In the six myosarcoma cell lines studied IR-A relative abundance ranged from 40 to 100% (median 87.5%) and was 595% in 3 -6 cell lines. In contrast, IR-A relative abundance ranged from 30 to 40% in normal muscle . In all six cell lines studied IGF-II, but not IGF-I, was produced in relevant amounts.
Interestingly, SKUT-1 leiomyosarcoma cells were found to express high levels of IR-A and to be IGF-IR deficient. In these cells IGF-IR was undetectable and exposure to IGF-I did not elicit any IGF-IR tyrosine phosphorylation. These cells were, therefore, used as a model to study the biological effects of both IGF-II and insulin via the IR-A, in the absence of the interfering activity of IGF-IR. In SKUT-1 cells both insulin and IGF-II were very poor growth promoters, as assessed by thymidine incorporation. Very similar results were obtained with Del-IGF-II, an IGF-II analog that does not bind to IGF-binding proteins, indicating that IGF-binding proteins are not responsible for the poor proliferative response to IGF-II.
Although IGF-II did not appreciably stimulate thymidine incorporation, it specifically increased MTT staining in cells maintained in serum-free medium. This effect was, therefore, mainly due to protection from apoptosis. Blockade of autocrine IGF-II by a monoclonal antibody markedly decreased unstimulated cell viability in serum-free medium. These data suggest that 'basal' IR-A activation by autocrine IGF-II production has a role in apoptosis control in SKUT-1 cells. In concert with these observations, both insulin and IGF-II protected SKUT-1 cells from staurosporin-induced apoptosis. Insulin was a slightly more potent anti-apoptotic agent than IGF-II, an expected consequence of the fact that insulin binds to and activates IR-A with higher affinity than IGF-II . Accordingly, insulin was a more potent stimulator of IR autophosphorylation and of the IRS-1/PI3K/Akt pathway, which plays a major role in apoptosis control (Barber et al., 2001; Hiromura et al., 2002) .
In contrast, IGF-II was significantly more potent than insulin in stimulating cell chemoinvasion. Autocrine IGF-II blockade by either a specific anti-IGF-II antibody or IGF-BP6 was able to reduce unstimulated SKUT-1 cell migration, suggesting a role for this autocrine loop in sustaining cell invasiveness.
A possible explanation for the strong invasionpromoting effect of IGF-II is the potent activation of the Shc/ERK pathway. These findings reinforce the suggestion that the two ligands (insulin and IGF-II), upon binding to the IR-A, preferentially activate either the IRS-1/PI3K/Akt pathway (insulin) or the Shc/ERK pathway (IGF-II) and have, therefore, a different potency in eliciting different biological effects. Inhibition of each pathway with specific inhibitors (LY290042 and PD98059) indicates that activation of both pathways is required to elicit the full chemoinvasion response to insulin and IGF-II. Blockade of either pathway resulted in 70 -90% inhibition of chemoinvasion response, while the two inhibitors in combination even at suboptimal concentrations completely inhibited ligand-induced chemoinvasion. These data are in agreement with previous reports indicating a role for both the PI-3K and the ERK pathway in insulin or IGF-I stimulated cell invasion in a variety of cell models (Bartucci et al., 2001; Imai and Clemmons, 1999) . They also suggest that the stronger ERK activation in response to IGF-II may have a role in the more effective chemoinvasion response to IGF-II as compared to insulin. These present data are reminiscent of previous findings in IGF-IR deficient murine fibroblasts (R 7 cells) transfected with the human IR-A cDNA. In that model IGF-II elicited a more potent mitogenic effect than insulin, whereas insulin had a more potent metabolic effect than IGF-II . Studies indicating a dissociation between the growth response and other biological effects elicited by IGF-II, are lacking, to our knowledge; however, it has recently been reported that IGF-I does not stimulate growth in estrogen receptor-negative human breast cancer cells, but it is effective in stimulating the same cell motility and invasiveness (Bartucci et al., 2001) .
In conclusion, these data show that an autocrine loop involving IGF-II and IR-A is active in both rhabdomyosarcoma and leiomyosarcoma cells, as previously described in epithelial malignancies Vella et al., 2002) . In cells coexpressing IR and IGF-IR, the predominant IR-A expression may lead to the formation of IR-A/IGF-IR hybrids and sensitize cells to IGFs and insulin, as previously described in different models . In SKUT-1 cells, which lack the IGF-IR, IR-A may vicariate for the IGF-IR, a major regulator of cell transformation, growth and apoptosis (Peruzzi et al., 1999; Rubin and Baserga, 1995) . Although IR-A activation by IGF-II (as well as by insulin) in these cells is a poor growth stimulator, it appears to be relevant to apoptosis protection and, especially, cell invasion. Therapeutical targeting of this autocrine loop may be, therefore, a valuable approach for adjuvant treatment of these highly aggressive malignancies.
Materials and methods
Materials
The following materials were purchased: Fetal Calf Serum (FCS), glutamine, gentamicin, were obtained from Gibco Laboratories (Paisley, UK); DMEM medium, RPMI medium, bovine serum albumin (BSA, radioimmunoassay grade), bacitracin, phenylmethylsulfonyl fluoride (PMSF), and porcine insulin from Sigma Chemical Co. (St. Louis, MO, USA); protein-A-Sepharose from Pharmacia (Uppsala, Sweden). IGF-I and IGF-II were obtained from Calbiochem Laboratories. Human Del(1 -6) IGF-II was obtained from Upstate Biotechnology Inc. (Lake Placid, NY, USA).
The following antibodies were employed: (a) anti-IR antibodies: MA-20 monoclonal antibody that recognizes IR a subunit (ID Goldfine, San Francisco, CA, USA) (Forsayeth et al., 1987; Roth et al., 1982) ; a rabbit polyclonal antibody that recognizes the IR b subunit (Transduction Laboratories, Lexington, KY, USA) and CT-1 monoclonal antibody that recognizes the IR b subunit (Ganderton et al., 1992) . (b) Anti-IGF-IR antibodies: aIR3 monoclonal antibody that recognizes IGF-IR a subunit (Kull et al., 1983 ) (Oncogene Research, Cambridge, MA, USA); chicken polyclonal antibody that recognizes IGF-IR a subunit (UBI, Lake Placid, NY, USA); 17 -69 monoclonal antibody that recognizes IGF-IR a subunit in both IGF-IR and Hybrid-R and 24 -60 monoclonal antibody that recognizes IGF-IR a subunit (K Siddle, Cambridge, UK).
Insulin receptor isoform A activation by insulin and IGF-II L Sciacca et al
Anti-phosphotyrosine 4G10, anti-IRS-1 and anti-IRS-2 polyclonal antibodies, anti-IGF-II monoclonal antibody were purchased from Upstate Biotechnology Inc. (Lake Placid, NY, USA); anti-Shc polyclonal antibody from Transduction Laboratories (Lexington, KY, USA); phosphospecific extracellular signal-related kinase (ERK) polyclonal antibody and anti-ERK polyclonal antibody, anti-phospho-AKT and anti-AKT antibodies were purchased from New England Biolabs (Beverly, MA, USA).
Cells
SKUT-1 and MESSA (leiomyosarcoma cells) and SJRH-30 (rabdomyosarcoma cells) were kindly provided by Dr Colombatti (Aviano, Italy). SKUT-1 and MESSA cells were routinely grown in DMEM supplemented with 10% fetal bovine serum; 1 mM Na Pyruvate was added to SKUT-1 cell culture. The SJRH-30 cells were routinely grown in RPMI supplemented with 10% fetal bovine serum.
Measurement of IGF-I and IGF-II production
IGF-I and IGF-II mRNA content in human sarcoma cell lines was evaluated by PCR. Total RNA was prepared from cells using Trizol RNA isolation reagent (Gibco BRL, Gaithersburg, MD, USA). First strand cDNA synthesis was performed on 4 -8 mg total RNA using M-MLV reverse transcriptase (Gibco BRL) and random hexamer primers (Pharmacia) in a total volume of 40 ml of 75 mM KCl, 50 mM Tris-HCl pH 8.3, 3 mM MgCl 2 , 0.5 mM dNTPs. PCR amplification was performed with 5 ml cDNA, adding 1.25 U Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA), 2.5 mM specific primers, 2.5 mM MgCl 2 , 0.2 mM dNTPs. The following primer sequences were used for IGF-II: 5'-3': GAA-GTC-GAT-GCT-GGT-GCT-TC and 3'-5': CTT-CCG-ATT-GCT-GGC-CAT-CT. For IGF-I: 5'-3': GAT-GCA-CAC-CAT-GTC-CTC-CT and 3'-5' TCC-TGC-GGT-GGC-ATG-TCA-CT. Conditions for PCR were: 948C630 s; 608C630 s; 728C630 s; 30 cycles. PCR products were resolved by electrophoresis on 5% polyacrilamide gel, and silver stained.
IGF-II protein secreted by cultured sarcoma cells in the conditioned media was measured by a commercial immunoradiometric assay that detects only the IGF-II mature form (BIOS, Naples, Italy) and expressed as M/48 h/10 6 cells.
IR and IGF-IR measurements
ELISA Receptors were captured by incubating cell lysates (0.5 -60 mg/well) in Maxisorp immunoplates pre-coated with 2 mg/ml of the specific monoclonal antibody indicated below. After washing, the immunocaptured receptors were incubated with the specific biotinylated monoclonal antibody indicated below (0.3 mg/ml in 50 mM HEPES-buffered saline, pH 7.6, containing 0.05% Tween 20, 1% BSA, 2 mM sodium orthovanadate, 1 mg/ml bacitracin and 1 mM PMSF) and then with peroxidase-conjugated streptavidin. The peroxidase activity was determined colorimetrically by adding 100 ml of 3,3',5,5'-tetramethylbenzidine (TMB, 0.4 mg/ml in 0.1 M citrate-phosphate buffer, pH 5.0 with 0.4 ml/ml of 30% H 2 O 2 ). The reaction was stopped by the addition of 1.0 M H 3 PO 4 and the absorbance measured at 450 nm. IRS were captured with anti-IR MA-20 antibody and detected with biotinylated anti-IR CT-1 antibody (Ganderton et al., 1992; Sciacca et al., 1999) . IGF-IRs were captured with anti-IGF-IR aIR-3 antibody and detected with biotinylated 17 -69 antibody (Kull et al., 1983) .
IR isoform measurements
IR isoform relative abundance was measured by RT -PCR, as previously described (Ebina et al., 1985; Sciacca et al., 1999) . Briefly, total cellular RNA was isolated from each cell line using Trizol RNA isolation reagent (Gibco BRL, Gaithersburg, MD, USA). First strand cDNA synthesis was performed on 4 -8 mg total RNA using M-MLV reverse transcriptase (Gibco BRL) and random hexamer primers (Pharmacia) in a total volume of 40 ml of 75 mM KCl, 50 mM Tris-HCl pH 8.3, 3 mM MgCl 2 , 0.5 mM dNTPs.
A cDNA synthesis reaction volume of 5 ml was combined in a 50 ml final reaction volume for PCR amplification containing 0.2 mM oligonucleotide primers spanning nucleotides 2230 -2251 (5'-AAC-CAG-AGT-GAG-TAT-GAG-GAT-3' and 2846 -2867 (5'-CCG-TTC-CAG-AGC-GAA-GTG-CTT-3') of the human insulin receptor and 1.25 U Taq DNA polymerase (AmpliTaq, Perkin-Elmer Cetus). PCR amplification was carried out for 30 cycles of 15 s at 958C, 30 s at 608C, and 45 s at 728C, using a DNA thermal cycler (Perkin-Elmer Cetus). Products of PCR amplification were resolved by electrophoresis on 5% polyacrylamide gel. The electrophoretic analysis showed the 600 and 636 bp DNA fragments representing Ex117 and Ex11+ IR isoforms, respectively. Gels were silver stained and band density quantified by scanning densitometry.
Insulin and IGF-I receptor autophosphorylation
Ligand activated IR and IGF-IR autophosphorylation in intact cells was measured by ELISA (Belfiore et al., 1996) and by Western blot. Cells in monolayer cultures were stimulated with increasing doses (0 -100 nM) of either insulin, IGF-II or IGF-I for 10 min at 378C.
For ELISA studies, cells were solubilized and receptors captured by incubating cell lysates (containing approximately 2 ng of receptor) in Maxisorp plates pre-coated with the anti-IR antibody MA-20 or with the anti-IGF-IR aIR3 antibody. After washing, biotinylated anti-phosphotyrosine antibody 4G10, 0.3 mg/ml (in 50 mM HEPES-buffered saline, pH 7.6, containing 0.05% Tween 20, 1% BSA, 2 mM sodium orthovanadate, 1 mg/ml bacitracin and 1 mM PMSF) was added to reveal phosphorylated receptors by the peroxidaseconjugated streptavidin method. The peroxidase activity was determined colorimetrically by adding 100 ml of TMB (0.4 mg/ml in 0.1 M citrate-phosphate buffer, pH 5.0 with 0.4 ml/ml of 30% H 2 O 2 ). The reaction was stopped by the addition of 1 M H 3 PO 4 and the absorbance measured at 450 nm.
For Western blot analysis confluent cells were incubated in serum-free medium for 48 h, stimulated with 10 nM of either insulin, IGF-II or IGF-I for 10 min at 378C and solubilized in RIPA buffer. Cell lysates were immunoprecipitated with anti-IR MA-20 antibody or with the anti-IGF-IR 24 -60 antibody and immunoblotting was performed using 4G10 anti-phosphotyrosine antibody. To show the amounts of receptors loaded in each lane, filters were subjected to stripping in Tris-HCl buffer (62.5 mM, pH 6.7) containing 2% SDS and 100 mM b-Mercapthoethanol for 30 min at 508C and reprobed with an anti-IR b-subunit polyclonal antibody or with a monoclonal anti-IGF-IR antibody. Immunoblots were revealed by an ECL method (Amersham, UK), autoradiographed and subjected to densitometric analysis.
IRS-1, IRS-2 and Shc phosphorylation in response to either insulin, IGF-I or IGF-II Subconfluent cells were incubated in serum-free medium for 24 h, stimulated with 10 nM of either insulin, IGF-II or IGF-I for 10 min at 378C and solubilized in RIPA buffer. Cell lysates were immunoprecipitated with either anti-IRS-1, or anti-IRS-2 or anti-Shc antibodies. Immunoblottings were performed using an anti-phosphotyrosine antibody (4G10). To show the amount of protein loaded in each lane, filters were first subjected to stripping in Tris-HCl buffer (62.5 mM, pH 6.7) containing 2% SDS and 100 mM b-Mercapthoethanol for 30 min at 508C. Next, filters containing IRS-1 were reprobed with an anti-IRS-1 polyclonal antibody, filters containing IRS-2 were reprobed with an anti-IRS-2 polyclonal antibody and filters containing Shc were reprobed with an anti-Shc polyclonal antibody. All the immunoblots were revealed by an ECL method (Amersham, UK), autoradiographed and subjected to densitometric analysis.
ERK1/2 and Akt phosphorylation in response to either insulin, IGF-I or IGF-II Subconfluent cells were washed twice with PBS (pH 7.4) and serum starved for 48 h. The cells were then treated with 10 nM of either insulin, IGF-I or IGF-II for 10 min. Ligand stimulation was terminated by two washes with ice-cold PBS (pH 7.4), buffer removal by aspiration and addition of icecold SDS sample buffer (62.5 mM Tris (pH 6.8), 10% glycerol, 2% SDS, 50 mM DTT, 0.1% bromophenol blue). After scraping, samples were sonicated for 10 s and heated to 95 -1008C for 5 min. Whole cell lysates were then subjected to reducing SDS -PAGE on 10% polyacrylamide gel. After electrophoresis, the resolved proteins were transferred to nitrocellulose membranes and subjected to immunoblot analysis. For ERK activation studies the blots were probed with a phospho specific anti-ERK polyclonal antibody. For Akt phosphorylation studies the blots were probed with an anti phospho-Akt polyclonal antibody. The nitrocellulose membranes were then stripped with stripping buffer for 30 min at RT and, subsequently, reprobed with either an anti-ERK polyclonal antibody or with an anti-Akt polyclonal antibody. All immunoblots were revealed by ECL method, autoradiographed and subjected to densitometric analysis. /well) were plated in 24-well tissue culture plates and grown in their regular medium for 24 h. The medium was then replaced with fresh medium containing 0.1% BSA. Twenty-four hours later, 10 nM of either insulin, IGF-II or IGF-I were added to each well. After 24 h, 18.5 KBq/well of [ 3 H]thymidine were added for 4 h. Cell monolayers were than washed twice with cold buffer, incubated with cold 10% TCA solution for 30 min, solubilized with 0.1 N NaOH and counted by liquid scintillation.
Cell growth studies
Viability assay
Cell viability was measured by the MTT test: cells (1610 3 / well) were seeded in 96-well plates. After 48 h, the medium was removed and replaced with BSA 0.1%. Cell viability was measured 6, 9 and 12 days later, by measuring the rate of tetrazolium salts reduction to formazan (MTT, Amersham Life Science, UK), which is proportional to the number of living cells (Heo et al., 1990) . At the end of incubation the absorbance was read at 540 nm.
Parallel wells were incubated with 2 mg/ml anti-IGF-II antibody with blocking activity or with 2 mg/ml control antibody anti-Py 4G10.
Apoptosis assay
Apoptosis in the cell cultures was determined with Cell Death Detection ELISA PLUS kit (Roche Diagnostic, Mannheim, Germany), a photometric enzyme-immunoassay for the qualitative and quantitative in vitro determination of cytoplasmic histone-associated-DNA-fragments after induced cell death. Briefly: cells (2610 4 /well) were plated in 12-well tissue culture plates and grown in their regular medium for 24 h. The medium was then replaced with fresh medium containing either insulin, IGF-I or IGF-II (10 nM) in the presence or absence of staurosporin at 2 nM for 24 h. At the end of incubation the absorbance was read at 405 nm.
Invasion assay
Cell ability to invade the matrigel was measured with the Boyden's chamber technique (Sieg et al., 1998) . Approximately 10 5 cells, resuspended in 100 ml of media, were placed on 6.5 mM diameter polycarbonate filters (8 mm pore size, Corning Costar Corporation, Cambridge, MA, USA) coated at the upper side with 1.2 mg/ml of matrigel (invasion assay). Either insulin, or IGF-II (10 nM) in 0.5 ml of medium was added to the lower compartment. Parallel wells were incubated with 0.5 mM HNMPA (hydroxy-2-naphthalenylmethyl phosphonic acid triacetoxymethyl ester), a specific IR tyrosine kinase inhibitor (Baltensperger et al., 1992) , with or without 10 nM insulin or IGF-II.
The plates were incubated at 378C with 5% CO 2 for 24 h and then the matrigel at the upper side of the filter was removed with a cotton swab. Cells that had migrated to the lower side of the filter were fixed with 11% glutheraldehyde for 15 min at room temperature and stained with 0.1% crystal violet in 20% methanol for 20 min. After three washes with water and complete drying, the crystal violet was solubilized by immersion of the filters in 10% acetic acid. The concentration of the solubilized crystal violet was evaluated as absorbance at 590 nm. To evaluate the effect of autocrine IGF-II production in sustaining unstimulated cell migration, cells seeded on polycarbonate filters were incubated in the presence or the absence of either 2 mg/ml anti-IGF-II antibody or control antibody (anti-Py 4G10) or 50 nM IGF-BP6 (Bach et al., 1994) . Cells migrated to the lower compartment were measured after 48 h incubation.
